<DOC>
	<DOC>NCT02644889</DOC>
	<brief_summary>This study has been designed in order to detect EGFR mutation abundance of tissue and concentration of plasma from Advanced Non-small Cell Lung Cancer during treatment with Tyrosine Kinase Inhibitor (TKI) .Through this experiment the investigators aim to evaluate the feasibility of plasma EGFR detection and evaluate the correlation of EGFR mutations and prognosis.</brief_summary>
	<brief_title>EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Age older than 18 years and under 75 years Histologically and cytologically proven nonsmall Cell Lung Cancer Clinical stages Ⅲ ~ Ⅳ Not receive any antitumor treatment Eastern cooperative oncology group performance status (ECOG PS) =1~2 Estimated survival time more than 3 months EGFRTKI treatment for firstline or secondline Voluntary to participate in this clinical trial and sign the consent form Patients have received EGFRTKI therapy before the study With other malignancy history in the recent 5 years before the study Pregnancy or breast feeding phase Inadequate samples for testing Followup compliance is poor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Epidermal growth factor receptor(EGFR)</keyword>
	<keyword>NSCLC</keyword>
</DOC>